Cited by 133TGF-β signaling in diseasesCancer-related Molecular PathwaysKruppel-like factors research

TGF-β1–induced expression of human Mdm2 correlates with late-stage metastatic breast cancer

Open access
Araki, Shinako, Eitel, Jacob A., Batuello, Christopher N., Bijangi-Vishehsaraei, Khadijeh, Xie, Xian-Jin, Danielpour, David, Pollok, Karen E., Boothman, David A. +1 more·2010·Journal of Clinical Investigation

Abstract

The E3 ubiquitin ligase human murine double minute (HDM2) is overexpressed in 40%-80% of late-stage metastatic cancers in the absence of gene amplification. Hdm2 regulates p53 stability via ubiquitination and has also been implicated in altering the sensitivity of cells to TGF-beta1. Whether TGF-beta1 signaling induces Hdm2 expression leading to HDM2-mediated destabilization of p53 has not been investigated. In this study, we report that TGF-beta1-activated SMA- and MAD3 (Smad3/4) transcription factors specifically bound to the second promoter region of HDM2, leading to increased HDM2 protein expression and destabilization of p53 in human cancer cell lines. Additionally, TGF-beta1 expression led to Smad3 activation and murine double minute 2 (Mdm2) expression in murine mammary epithelial cells during epithelial-to-mesenchymal transition (EMT). Furthermore, histological analyses of human breast cancer samples demonstrated that approximately 65% of late-stage carcinomas were positive for activated Smad3 and HDM2, indicating a strong correlation between TGF-beta1-mediated induction of HDM2 and late-stage tumor progression. Identification of Hdm2 as a downstream target of TGF-beta1 represents a critical prosurvival mechanism in cancer progression and provides another point for therapeutic intervention in late-stage cancer.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1172/jci39194

Cites

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

The citation lists haven’t been fetched yet

References 60 · Cited by 133

Research works printed but not linked: 1

  1. Criswell TL, et al. Delayed activation of IGF- 1R/Src/MAPK/Egr-1 signaling regulates clus- terin expression, a pro-survival factor. J Biol Chem. 2005;280(14):14212-14221.

Authors
Araki, S., Eitel, J. A., Batuello, C. N., Bijangi-Vishehsaraei, K., Xie, X.-J., Danielpour, D., Pollok, K. E., Boothman, D. A., & Mayo, L. D.
Affiliations
  • Harold C. Simmons Comprehensive Cancer Center (US)
  • Indiana University Indianapolis (US)
  • Case Comprehensive Cancer Center (US)
  • Indiana University – Purdue University Indianapolis (US)
Venue
Journal of Clinical Investigation
Published
2010-01-04
Volume
120
Issue
1
Pages
290-302
ISSN
0021-9738 (ISSN-L)
OpenAlex
W2124433932
Cited by
133
References
60
Citations by year
2026: 2 · 2025: 2 · 2024: 6 · 2023: 5 · 2022: 3 · 2021: 7 · 2020: 4 · 2019: 11 · 2018: 4 · 2017: 8 · 2016: 2 · 2015: 5 · 2014: 16 · 2013: 12 · 2012: 26
FWCI
6.18
Type
journal article
Language
en
Open access
Locations
  • Journal of Clinical Investigation (publishedVersion)
  • Europe PMC (PubMed Central) (publishedVersion)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • U.S. Department of Energy (DE-FG02-09ER64789, DE‐FG02‐)
  • National Institutes of Health (NIH-R01)
  • National Cancer Institute (R01CA139217, P30CA08709, R01CA109262, R01CA102792, P30CA142543)
  • National Institute of Allergy and Infectious Diseases (U19AI067773)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › TGF-β signaling in diseases
  • Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Kruppel-like factors research
Keywords
TGF-β1, MDM2, Smad3, SMAD4, breast cancer metastasis, epithelial-mesenchymal transition, transcriptional regulation, tumor progression, E3 ubiquitin ligase
MeSH terms
Breast Neoplasms, Female, Humans, Imidazoles, Neoplasm Staging, Piperazines, Promoter Regions, Genetic, Gene Expression Regulation, Neoplastic, Tumor Suppressor Protein p53, Apoptosis, HCT116 Cells, Proto-Oncogene Proteins c-mdm2, Smad3 Protein, Transforming Growth Factor beta1

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review